CA Patent

CA2614048A1 — Improved crystalline form of the compound a-348441

Assigned to Karo Healthcare AB · Expires 2007-01-18 · 19y expired

What this patent protects

There is provided a hemihydrate of (3.beta., 5.beta., 7.alpha., 12.alpha.) -7 , 12- dihydroxy-3-{2- [ {4- [17.beta.-hydroxy-3-oxo-17.alpha.-prop-l-ynylestra-4 , 9-dien-ll.beta.-yl] phenyl } (methyl) amino] ethoxy} cholan-24-oic acid in a crystalline form which is characterised by…

USPTO Abstract

There is provided a hemihydrate of (3.beta., 5.beta., 7.alpha., 12.alpha.) -7 , 12- dihydroxy-3-{2- [ {4- [17.beta.-hydroxy-3-oxo-17.alpha.-prop-l-ynylestra-4 , 9-dien-ll.beta.-yl] phenyl } (methyl) amino] ethoxy} cholan-24-oic acid in a crystalline form which is characterised by an X-ray diffraction pattern having major peaks at 2.theta. = 6.58~0.2, 8.54+0.2, 12.28~0.2, and 19.68~0.2. This crystalline material is useful in the treatment of conditions associated with an excess of hepatic glucocorticoid response.

Drugs covered by this patent

Patent Metadata

Patent number
CA2614048A1
Jurisdiction
CA
Classification
—
Expires
2007-01-18
Drug substance claim
No
Drug product claim
No
Assignee
Karo Healthcare AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.